Skip to main content
CONTEC MEDICAL SYSTEMS CO., LTD. logo

CONTEC MEDICAL SYSTEMS CO., LTD. — Investor Relations & Filings

Ticker · 300869 ISIN · CNE1000047F0 LEI · 6556007SL3V6YKCWVA55 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 789 across all filing types
Latest filing 2022-08-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300869

About CONTEC MEDICAL SYSTEMS CO., LTD.

https://www.contecmed.com.cn

CONTEC Medical Systems Co., Ltd. focuses on the research, development, manufacturing, and distribution of medical electronic instruments. The product portfolio encompasses a wide range of diagnostic and monitoring solutions, including pulse oximeters, blood pressure monitors, electrocardiographs, ultrasound equipment, and multi-parameter patient monitors. Additionally, the company provides specialized devices such as fetal monitors, sleep apnea screening systems, and biochemical analyzers. By leveraging integrated research and large-scale production facilities, the organization delivers medical technology designed for clinical, hospital, and home healthcare environments. The company emphasizes technical innovation and adheres to international quality standards to ensure the precision and reliability of its medical hardware and software solutions.

Recent filings

Filing Released Lang Actions
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2022 年半年度报告全文" which translates to "2022 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company overview, industry analysis, and other comprehensive information typical of an interim or quarterly report. The report period is specified as January 1, 2022 to June 30, 2022, confirming it covers a half-year period. The document length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-26 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 Half-Year Report Summary' (半年度报告摘要) for 康泰医学系统（秦皇岛）股份有限公司, indicating it is a summary of the company's interim financial report. It contains detailed financial data such as revenue, net profit, earnings per share, asset and equity figures, shareholder information, and bond issuance details for the half-year period. The document is about 2880 characters, which is typical for a summary but contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. It is not a full Annual Report (10-K), nor is it a simple announcement or regulatory filing. Hence, the correct classification is IR with high confidence. H1 2022
2022-08-26 Chinese
独立董事关于第三届董事会第二十一次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on matters discussed at the 21st meeting of the third board of directors of 康泰医学系统（秦皇岛）股份有限公司. It includes independent opinions on the 2022 half-year fundraising fund usage report, confirmation of forward foreign exchange settlement business, and special statements on related party fund occupation and external guarantees. The document is a formal opinion letter by independent directors, referencing compliance with laws and regulations, but it does not contain actual financial statements or detailed financial data. The document length is short (1339 characters) and it serves as a formal opinion or certification related to board meeting matters rather than a full financial report or audit. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related filing and independent director opinion rather than a full report or announcement of a report.
2022-08-26 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 21st meeting of the third board of directors of Kangtai Medical System (Qinhuangdao) Co., Ltd. It includes details about the meeting date, attendance, and the approval of several proposals including the 2022 semi-annual report and its summary, a special report on the use of raised funds, and confirmation of forward foreign exchange settlement business. The document references the actual reports being published on the designated disclosure website but does not contain the full reports or detailed financial data itself. The document is primarily about board meeting decisions and disclosures related to management and governance matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1696 characters), and it is not the report itself but an announcement of board resolutions and approvals.
2022-08-26 Chinese
关于补充确认公司开展远期结售汇业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 康泰医学系统（秦皇岛）股份有限公司 regarding the supplementary confirmation of the company's forward foreign exchange settlement and sales business. It details the board and supervisory meetings held to approve this business, the nature and purpose of the forward foreign exchange contracts, risk analysis, risk control measures, and opinions from the board, independent directors, supervisory board, and sponsoring institution. The document does not contain financial statements or detailed financial performance data but is a regulatory disclosure about a specific business activity and its internal approvals. It is not a full financial report, earnings release, or management discussion. It is also not a report publication announcement since it contains substantive information about the business activity and approvals. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-08-26 Chinese
康泰医学系统（秦皇岛）股份有限公司关于开展远期结售汇业务的可行性分析报告
Audit Report / Information Classification · 95% confidence The document is a detailed feasibility analysis report regarding the company's forward foreign exchange settlement business. It discusses the purpose, necessity, risk analysis, risk control measures, and accounting policies related to this specific financial activity. The content is focused on explaining and justifying a particular financial operation rather than announcing a report, voting results, or management changes. It does not contain quarterly or annual financial statements or earnings highlights, so it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a regulatory filing or certification. The document is a standalone report analyzing a financial risk management activity, which fits best under Audit Report / Information (AR) as it involves accounting principles and risk assessment related to financial instruments. H1 2022
2022-08-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.